India's Supreme Court has rejected a request by Swiss drug-maker Novartis to patent an updated version of its cancer drug Glivec.<br /><br />Glivec costs around 2,000 euros per month whereas the domestically produced generic equivalent costs around 140 euros.<br /><br />The judgement is supported by healthcare activists who want the government to make medicines cheaper.<br /><br />...<br />No Comment | euronews: watch the international news without commentary | http://www.euronews.net/nocomment/
